Scribd Logo
Carica

Benvenuto in Scribd!

  • Challenges Translating Breast Cancer Gene Signatures Into The Clinic

    Caricato da

    sweetie05
    7 visualizzazioni7 pagine
    A journal paper on breast cancer

    Titolo originale

    Challenges Translating Breast Cancer Gene Signatures into the Clinic

    Copyright

    © © All Rights Reserved

    Formati disponibili

    PDF o leggi online da Scribd

    Hai trovato utile questo documento?

    Questo contenuto è inappropriato?

    Segnala questo documento
    A journal paper on breast cancer

    Copyright:

    © All Rights Reserved
    Scarica in formato PDF o leggi online su Scribd
    Segnala contenuti inappropriati
    7 visualizzazioni7 pagine

    Challenges Translating Breast Cancer Gene Signatures Into The Clinic

    Caricato da

    sweetie05
    A journal paper on breast cancer

    Copyright:

    © All Rights Reserved
    Scarica in formato PDF o leggi online su Scribd
    Segnala contenuti inappropriati
    di 7
    PERSPECTIVES OPINION Challenges translating breast cancer gene signatures into the clinic Britta Weigelt, Lajos Pusztai, Alan Ashworth and Jorge S. Reis Filho Abstract | The advent of microarray-based gene-expression profiling a decade '8g0 raised high expectations for rapid advances in breast cancer classification, prognostication and prediction. Despite the development of molecular classifications, and prognostic and predictive gene-expression signatures, microarray-based studies have not yielded definitive answers to many of the questions that remain germane ‘or the successful implementation of personalized medicine. There are a lack of Fobust signatures to predict benefit from specific therapeutic agents and itis still not possible to predict prognosis or chemotherapy treatment response in specific disease subsets accurately, such as triple-nogative breast cancer. We discuss the hurdles in ‘the development and validation of molecular classification systems, and prognostic and predictive signatures based on microarray gene expression profiling. We suggest ‘that similar challonges are likely to bo encountered in translating next generation. sequencing data into clinically useful information. Finally we highlight strategies for the development of clinically useful molecular predictors in the future. ‘Weg eo Ne Re. Cin. eat 9, 58-68 2022} pushes anne 30 August 2024: ‘10 1008/recinone 2 Introduction Traditionally, the choice of therapy offered tocancer patients is based on their estimated prognosis, which is mostly derived from, anatomical and pathological features ofthe cancer, comorbidities, and risk of adverse fects from therapy. For example, patients ‘with poor-prognosis breast cancer who ate relatively ft are usually offered adjuvant chemotherapy; but many eceive litle benefit ‘rom this treatment" An important limita ton ofthis strategy is that most anatomical and histological features that predict prog: nosis, particularly tumor size or lymph-node status, do not predict sensitivity to chemo: therapy. In the past decade, hoviever, con-

    Potrebbero piacerti anche